Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux

Fan Lin, Mark C de Gooijer, Diana Hanekamp, Dieta Brandsma, Jos H Beijnen, Olaf van Tellingen

Research output: Contribution to journalReview articleAcademicpeer-review


High-grade gliomas are the most common type of primary brain tumor and are among the most lethal types of human cancer. Most patients with a high-grade glioma have glioblastoma multiforme (GBM), the most malignant glioma subtype that is associated with a very aggressive disease course and short overall survival. Standard treatment of newly diagnosed GBM involves surgery followed by chemoradiation with temozolomide. However, despite this extensive treatment the mean overall survival is still only 14.6 months and more effective treatments are urgently needed. Although different types of GBMs are indistinguishable by histopathology, novel molecular pathological techniques allow discrimination between the four main GBM subtypes. Targeting the aberrations in the molecular pathways underlying these subtypes is a promising strategy to improve therapy. In this article, we will discuss the potential avenues and pitfalls of molecularly targeted therapies for the treatment of GBM.

Original languageEnglish
Pages (from-to)271-88
Number of pages18
JournalCNS Oncology
Issue number3
Publication statusPublished - May 2013

Cite this